CITY OF INDUSTRY, Calif., Feb. 18, 2005 (PRIMEZONE) -- U.S. BioDefense, Inc. (OTCBB:UBDE) announces that they will be attending the Internationalizing Early-Stage Clinical Drug Research & Development Conference, being hosted at The Stadium Club at Dodger Stadium in Los Angeles, CA on Thursday, March 3rd, 2004. Panelists (http://www.losangeles.gc.ca/) include Mr. David Mee of Amgen (Nasdaq:AMGN), Dr. Bruce Morimoto of MDS Pharma Services, and Dr. Jim Gallivan of Health Canada.
"We are very excited to be a part of this event which will allow us the opportunity to meet face-to-face with developers, scientists, investors and executives of hand-selected biotech and gene-therapy companies with tremendous potential for growth. Recent changes to regulations governing clinical research in Canada are allowing researchers and biotech companies to see new opportunities and experience positive results," said David Chin, CEO of U.S. BioDefense.
U.S. BioDefense, a Department of Defense central contractor that researches, develops, and commercializes leading-edge biotechnology, recently announced a new stem cell separation and insertion technology license agreement with a major University. It has filed its Small Business Innovation Research (SBIR) Grant proposal Number C051-117-0060 with the Department of Defense Chemical Biological Defense Agency in response to SBIR (dodsbir.net) Topic number CBD05-117 'Stem Cell Technology and Autologous Bioengineered Skin for the Treatment of Cutaneous Vesicant Injury'
About the Canadian Consulate
The Consulate General is located in downtown Los Angeles, and International Trade Canada (ITCan) is responsible for positioning Canada as a world business leader for the 21st Century. ITCan accomplishes this by helping large and small Canadian companies expand and succeed internationally, by promoting Canada as a dynamic place to do business, and by negotiating and administering trade agreements.
About U.S. BioDefense, Inc.
U.S. BioDefense is a Department of Defense central contractor that researches, develops, and commercializes leading-edge biotechnology. U.S. BioDefense recently announced a new stem cell separation and insertion technology license agreement with a major University. It has filed its Small Business Innovation Research (SBIR) Grant proposal Number C051-117-0060 with the Department of Defense Chemical Biological Defense Agency in response to SBIR (dodsbir.net) Topic number CBD05-117 'Stem Cell Technology and Autologous Bioengineered Skin for the Treatment of Cutaneous Vesicant Injury'. U.S. BioDefense recently sponsored the Project T2 Technology Transfer Conference, the nation's leading showcase of new university technologies, being hosted at the Wilshire Grand Hotel in Los Angeles, CA. Other sponsors (http://www.projectt2.org/sponsors.htm) include Southern California Edison, Latham & Watkins, Morrison & Foerster, PricewaterhouseCoopers, Canadian Consulate General, and Genzyme (Nasdaq:GENZ). U.S. BioDefense, Inc. recently entered into a Commercial Evaluation License Agreement with the National Institutes of Health (NIH). The biotechnology is related to a method for universal inactivation of viruses, parasites and tumor cells. These inactivated agents can be used as vaccines against the diseases caused by such viruses, parasites and tumor cells. Hence, the immunogenic of the agent as a whole is maintained and can be safely used for vaccination without the threat of infection. U.S. BioDefense, Inc. intends to conduct laboratory experiments under this Agreement to evaluate the suitability for commercial development. Furthermore, U.S. BioDefense, Inc. has agreed to provide the facilities, personnel, and expertise to evaluate the commercial applications. The company recently published its white paper on Stem Cell technology transfer analyzing California University and industry participants intellectual property resources including ViaCell (Nasdaq:VIAC), Geron (Nasdaq:GERN), Aastrom Biosciences (Nasdaq:ASTM), and StemCells, Inc. (Nasdaq:STEM).